Galmed Pharmaceuticals Ltd. (GLMD)
Nasdaq: GLMD · Pharmaceutical Preparations · Ramat Gan, IL · filing with the SEC since 2013
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
| Report filed | Mar 31, 2026 | Apr 2, 2025 | Apr 4, 2024 | Mar 29, 2023 | May 2, 2022 | Mar 18, 2021 | Mar 12, 2020 | Mar 13, 2019 | Mar 13, 2018 | Mar 23, 2017 |
| Revenue | · | · | · | · | · | 0 | 0 | 2,038 | 1,085 | 467 |
| Research and development | 4,874 | 2,979 | 3,569 | 12,995 | 27,220 | 26,082 | 18,180 | 8,313 | 9,650 | 14,271 |
| General and administrative | 3,636 | 3,299 | 3,923 | 4,656 | 5,661 | 4,128 | 4,196 | 4,440 | 3,799 | 3,078 |
| Total operating expenses | 8,510 | 6,278 | 7,492 | 17,651 | 32,881 | 30,210 | 22,376 | 10,715 | 12,364 | 16,882 |
| Operating income | · | · | · | · | · | -30,210 | -22,376 | -10,715 | -12,364 | · |
| Interest and investment income | · | · | · | · | · | 1,192 | 1,953 | 959 | 202 | 382 |
| Share of profit of equity-method investments | · | 7 | · | · | · | · | · | · | · | · |
| Other income (expense), net | 741 | 516 | 580 | -215 | 414r | 1,439 | -1,915r | 934 | 65 | 35 |
| Total non-operating income (expense) | -741 | -516 | -580 | · | · | · | · | · | 65 | 35 |
| Income before income taxes | · | 7,517 | 6,912r | 17,866r | -32,467 | -28,771 | -20,461 | -9,781 | -12,299 | -16,847 |
| Income tax expense | 0 | · | · | · | · | 0 | 0 | 75 | 0 | 106 |
| Net income including non-controlling interests | 6,900 | 7,500r | 10,300r | 17,900r | 32,400 | -28,800r | 20,500r | -9,856 | -12,299 | -16,953 |
| Net income | -10,309 | -7,517 | -6,912 | -17,866 | -32,467 | -28,771 | -20,461 | · | · | · |
| Earnings per share, basic | 2.39 | 8.08 | 30.00r | 127.80r | 237.60rb | 16.20b | 11.64b | · | · | · |
| Earnings per share, diluted | 2.39 | 8.08 | 30.00r | 127.80r | 237.60b | · | · | · | · | · |
| Weighted average shares, basic | 4,311,323 | 930,822 | 230,795r | 139,682r | 136,654b | · | · | · | · | · |
| Weighted average shares, diluted | 4,311,323 | 930,822 | 230,795r | 139,682r | 136,654rb | 1,773,399b | 1,759,533b | · | · | · |
| Weighted average shares, basic and diluted | · | · | · | · | · | 1,773,399b | 1,759,533b | 1,511,474b | 1,040,612b | 947,888b |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 1-for-12 reverse split.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:Revenues
us-gaap:SalesRevenueNetResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest and investment income what its cash and investments earned
us-gaap:InterestIncomeOtherShare of profit of equity-method investments its share of companies it partly owns
us-gaap:IncomeLossFromEquityMethodInvestmentsOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted